Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease
| Autor: | Tejas V. Patel |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Canagliflozin
Cardiovascular event Kidney medicine.medical_specialty business.industry MEDLINE General Medicine Type 2 diabetes medicine.disease Nephropathy medicine.anatomical_structure Diabetes Mellitus Type 2 Diabetes mellitus Internal medicine Internal Medicine medicine Humans Renal Insufficiency Chronic business Sodium-Glucose Transporter 2 Inhibitors medicine.drug Kidney disease |
| Zdroj: | Annals of Internal Medicine. 171:JC15 |
| ISSN: | 0003-4819 |
| Popis: | Source Citation Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295-306. 30990260 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|